Stock Analysis·← Pickers

EVMN

Evommune, Inc.

Evommune, Inc. (EVMN) is currently in a range/mixed trend. RSI is at 32.1, with 0/3 trend checks passing.

Price
$12.45
2026-07-16
Trend score
0/3
Range / Mixed
RSI (14)
32.1
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

EVMN with MA50 and MA200

31.5726.6821.7816.8911.9911/0601/0903/1205/1307/15
EVMN2025-11-062026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$19.99-37.73% vs price
MA200
Distance unavailable
RSI (14)
32.1Neutral zone
MACD Signal
BearishMomentum below signal
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Chart Summary
Trend summary for EVMN

Evommune, Inc. (EVMN) currently looks more uncertain than directional, with a fairly mixed technical picture. The latest available price is $12.45, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 37.7%.

Momentum and stretch context

EVMN currently has an RSI reading of 32.1, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.

What traders may watch next

This page is designed to help you quickly understand what the EVMN chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.

Company profile

About Evommune, Inc.

Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Luis C. Pena
Employees
48
Market cap
$176.3M
Beta
0.86
52-week range
$11.55 – $33.20
Dividend
No
Exchange
NYSE
Country
US
IPO date
6 Nov 2025
ISIN
US30054Y1073
CUSIP
30054Y107
Company profile data from Financial Modeling Prep. EVMN listed on NYSE.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about EVMN

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.